Cargando…

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus

OBJECTIVE: Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel measure of type I IFN activity and serum/plasma biomarker in large independent cohorts of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Christoffer T, Lood, Christian, Østergaard, Ole, Iversen, Line V, Voss, Anne, Bengtsson, Anders, Jacobsen, Søren, Heegaard, Niels H H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246916/ https://www.ncbi.nlm.nih.gov/pubmed/25452879 http://dx.doi.org/10.1136/lupus-2014-000026

Ejemplares similares

Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus
por: Østergaard, Ole, et al.
Publicado: (2017)

A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus
por: Nielsen, Christoffer T., et al.
Publicado: (2017)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Type I Interferon-Mediated Skewing of the Serotonin Synthesis Is Associated with Severe Disease in Systemic Lupus Erythematosus
por: Lood, Christian, et al.
Publicado: (2015)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study
por: Compagno, Michele, et al.
Publicado: (2014)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis
por: Iversen, Line V., et al.
Publicado: (2015)

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus
por: Raymond, Warren David, et al.
Publicado: (2021)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus
por: Matsueda, Yu, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus
por: Yerram, Keerthi Vardhan, et al.
Publicado: (2023)

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
por: Wallace, Daniel J, et al.
Publicado: (2016)

Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus
por: Hirohata, Shunsei, et al.
Publicado: (2019)

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
por: Merola, Joseph F, et al.
Publicado: (2021)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2022)

sIL7R concentrations in the serum reflect disease activity in the lupus kidney
por: Lauwerys, B R, et al.
Publicado: (2014)

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up
por: Schoindre, Yoland, et al.
Publicado: (2014)

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density
por: Shevchuk, Sergii, et al.
Publicado: (2023)

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
por: Brunekreef, Tammo, et al.
Publicado: (2021)

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
por: Anderson, Erik W, et al.
Publicado: (2021)

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
por: Alexander, Roberta Vezza, et al.
Publicado: (2021)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Microparticles from patients with systemic lupus erythematosus induce production of reactive oxygen species and degranulation of polymorphonuclear leukocytes
por: Winberg, Line Kjær, et al.
Publicado: (2017)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus
por: Kalinska-Bienias, Agnieszka, et al.
Publicado: (2020)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus
por: Faustini, Francesca, et al.
Publicado: (2022)

Neutrophil FcγRIIA availability is associated with disease activity in systemic lupus erythematosus
por: Bengtsson, Anders A., et al.
Publicado: (2020)

KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells
por: Zheng, Yujia, et al.
Publicado: (2023)

Stimulation of Mononuclear Cells Through Toll-Like Receptor 9 Induces Release of Microvesicles Expressing Double-Stranded DNA and Galectin 3-Binding Protein in an Interferon-α-Dependent Manner
por: Rasmussen, Niclas Stefan, et al.
Publicado: (2019)

Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic sclerosis
por: Andraos, Rama, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uer5c86tht6iq58nj3u2jo1ar1